Jennifer Marks, Physician at shared a post on X:
“Thyroid Cancer Highlights for Boards Early PTC/FTC: Surgery + RAI + TSH Suppression in adv setting: 1L sorafenib; lenvatinib; 2L cabozantinib (PTC, FTC) 1L vandetanib; cabozantinib (MTC).”
Others:
- BRAF V600E (PTC>>ATC)
- RET (MTC)
- NTRK
- ALK
Source: Jennifer Marks/X